Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Phase of Trial: Phase II
Latest Information Update: 04 May 2016
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome
- Focus Adverse reactions
- Sponsors Lexicon Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 31 Mar 2016 Results from the qualitative interview study (n=11) published in the Clinical Therapeutics.
- 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.